Theranostics has delivered major success stories in prostate cancer and somatostatin receptor-positive tumors. For Prof. Ken Herrmann, however, the bigger question is what comes next.
The director of nuclear medicine at University Hospital Essen sees major potential in moving radioligand therapy into earlier treatment settings, finding targets for a broader range of cancers, and combining total-body PET with very low radiation doses and novel diagnostic concepts.
In this video interview Herrmann also discusses his priorities as incoming editor-in-chief of the Journal of Nuclear Medicine. He reflects on the changing publishing landscape, explains why genuinely novel data and strong trial design will remain indispensable, and shares his ambitions for Essen’s new Theranostics Center of Excellence.
For a deeper dive, read the Q&A, in which Herrmann discusses the evidence needed to move radioligand therapy into earlier treatment lines, the challenge of translating promising research into routine care, growing interest among young professionals, and the importance of addressing long-term toxicity with honesty and transparency.
